Bio-Path shares rally after clinical trial progress of BP1002

seekingalpha04-18

Shares of Bio-Path Holdings (NASDAQ:BPTH) jumped more than 100% on Thursday, after the company reported an update from the Phase 1/1b clinical trial of BP1002, evaluating the drug candidate's ability ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428616513?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1203934257/image_1203934257.jpg","is_english":true,"pubTime":"2024-04-18 22:55","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2428616513","market":"fut","top_or_hot":-1,"title":"Bio-Path shares rally after clinical trial progress of BP1002","media":"seekingalpha","content":"<div>\n<p>Shares of Bio-Path Holdings (NASDAQ:BPTH) jumped more than 100% on Thursday, after the company reported an update from the Phase 1/1b clinical trial of BP1002, evaluating the drug candidate's ability ...</p>\n\n<a href=\"https://seekingalpha.com/news/4091082-bio-path-shares-rally-after-clinical-trial-progress-of-bp1002\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Path shares rally after clinical trial progress of BP1002</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Path shares rally after clinical trial progress of BP1002\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-18 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4091082-bio-path-shares-rally-after-clinical-trial-progress-of-bp1002><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Bio-Path Holdings (NASDAQ:BPTH) jumped more than 100% on Thursday, after the company reported an update from the Phase 1/1b clinical trial of BP1002, evaluating the drug candidate's ability ...</p>\n\n<a href=\"https://seekingalpha.com/news/4091082-bio-path-shares-rally-after-clinical-trial-progress-of-bp1002\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4091082-bio-path-shares-rally-after-clinical-trial-progress-of-bp1002","article_id":"2428616513","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1203934257/image_1203934257.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428616513","pubTimestamp":1713452149,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Shares of Bio-Path Holdings (NASDAQ:BPTH) jumped more than 100% on Thursday, after the company reported an update from the Phase 1/1b clinical trial of BP1002, evaluating the drug candidate's ability ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BPTH":"Bio-Path Holdings, Inc."},"translate_title":"BP1002临床试验进展后生物路径股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BPTH":1},"content_text":"Shares of Bio-Path Holdings (NASDAQ:BPTH) jumped more than 100% on Thursday, after the company reported an update from the Phase 1/1b clinical trial of BP1002, evaluating the drug candidate's ability to treat refractory/relapsed acute myeloid leukaemia patients. Bio-Path (BPTH) stock, which shed 65% YTD, gained +112.65% on the day.  “We are delighted to safely progress through the second, higher dose cohort to reach an important study milestone for the United States Food and Drug Administration to review patient study data,” CEO Peter Nielsen said. BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients, Bio-Path Holdings (BPTH) said. Source: Press Release    More on Bio-Path  Seeking Alpha’s Quant Rating on Bio-Path Historical earnings data for Bio-Path Financial information for Bio-Path","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428616513"}